KR20220048640A - Cosmetic composition, pharmaceutical composition, and food composition comprising pterocaria stenoptera extract, which have anti-inflammatory immune activity and antioxidant activity and provide excellent effect on muscle cell generation for strengthening muscle strength or muscle in the elderly - Google Patents
Cosmetic composition, pharmaceutical composition, and food composition comprising pterocaria stenoptera extract, which have anti-inflammatory immune activity and antioxidant activity and provide excellent effect on muscle cell generation for strengthening muscle strength or muscle in the elderly Download PDFInfo
- Publication number
- KR20220048640A KR20220048640A KR1020200131756A KR20200131756A KR20220048640A KR 20220048640 A KR20220048640 A KR 20220048640A KR 1020200131756 A KR1020200131756 A KR 1020200131756A KR 20200131756 A KR20200131756 A KR 20200131756A KR 20220048640 A KR20220048640 A KR 20220048640A
- Authority
- KR
- South Korea
- Prior art keywords
- stenoptera
- ethanol extract
- inflammatory
- composition
- disease
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 34
- 235000013305 food Nutrition 0.000 title claims abstract description 32
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 30
- 230000005965 immune activity Effects 0.000 title claims abstract description 27
- 239000002537 cosmetic Substances 0.000 title claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 241000760908 Stenoptera Species 0.000 title claims description 37
- 239000000284 extract Substances 0.000 title description 12
- 230000000694 effects Effects 0.000 title description 10
- 210000003205 muscle Anatomy 0.000 title description 7
- 210000000663 muscle cell Anatomy 0.000 title description 5
- 238000005728 strengthening Methods 0.000 title description 5
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 55
- 201000010099 disease Diseases 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 241001051053 Garcinia cowa Species 0.000 claims description 20
- 241001330462 Nageia fleuryi Species 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 14
- 241000593508 Garcinia Species 0.000 claims description 11
- 235000000885 Garcinia xanthochymus Nutrition 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 11
- 208000027866 inflammatory disease Diseases 0.000 claims description 11
- 230000032683 aging Effects 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 241000758797 Pterocarya Species 0.000 claims description 7
- -1 skin Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims description 2
- 208000027496 Behcet disease Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000014644 Brain disease Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000011200 Kawasaki disease Diseases 0.000 claims description 2
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 2
- 201000010927 Mucositis Diseases 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 201000009623 Myopathy Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010038910 Retinitis Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 201000009961 allergic asthma Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 230000003412 degenerative effect Effects 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 241001493065 dsRNA viruses Species 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 201000008319 inclusion body myositis Diseases 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 239000003380 propellant Substances 0.000 claims description 2
- 241000114864 ssRNA viruses Species 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims 1
- 239000004531 microgranule Substances 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000023516 stroke disease Diseases 0.000 claims 1
- 241000305548 Pterocarya stenoptera Species 0.000 abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 17
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000419 plant extract Substances 0.000 description 8
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 5
- 241001489185 Nageia Species 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 230000002407 ATP formation Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000001076 sarcopenia Diseases 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 235000013555 soy sauce Nutrition 0.000 description 2
- 239000010421 standard material Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- QKPLRMLTKYXDST-NSEZLWDYSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;hydrochloride Chemical compound Cl.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O QKPLRMLTKYXDST-NSEZLWDYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241001487832 Cupressus duclouxiana Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940089491 hydroxycitric acid Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000021264 seasoned food Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 항염증 면역활성 및 항산화 활성을 가지며, 노인의 근력 또는 근육 강화를 위한 근세포 조성에 우수한 효과를 제공하는 프테로카리아 스테놉테라 추출물을 포함하는 화장료 조성물, 약학적 조성물, 및 식품 조성물에 관한 것이다. The present invention provides a cosmetic composition, a pharmaceutical composition, and a food composition comprising an extract of Pterocaria stenoptera, which has anti-inflammatory immune and antioxidant activity, and provides an excellent effect on the composition of muscle cells for muscle strength or muscle strengthening in the elderly is about
최근 국민 소득의 향상 및 급격한 경제 성장으로 인하여, 영양과다, 운동부족, 과도한 음주 그리고 심한 흡연 등과 같은 건강 위협 요인들에 대한 노출 가능성이 높아지고 있다. 따라서, 이로 인해 생기기 쉬운 질병 예방 및 회복, 노화 억제 등을 위한 기능성 건강제품에 대한 관심이 점차 높아지고 있다(Oh et al., 2016). Due to the recent improvement in national income and rapid economic growth, the possibility of exposure to health-threatening factors such as overnutrition, lack of exercise, excessive drinking and heavy smoking is increasing. Therefore, interest in functional health products for preventing and recovering from diseases that are prone to this, and inhibiting aging, is gradually increasing (Oh et al., 2016).
노화와 질병은 인체대사 중 산화반응에 기인하며, 이 과정 중에 만들어지는 활성산소는 불안정하고 산화력이 높아 생체 내 물질과 쉽게 반응하기 때문에 산화적 스트레스를 유발하게 된다. 이러한 산화적 스트레스는 단백질, 탄수화물 지질 및 DNA와 반응하여 여러 조직의 세포를 손상시켜 당뇨, 비만, 동맥경화, 치매 등 다양한 질병을 유발할 수 있다(Kim et al., 2008). Aging and disease are caused by oxidative reactions during human metabolism, and the free radicals produced during this process are unstable and have high oxidative power, which causes oxidative stress because they react easily with substances in the body. This oxidative stress can cause various diseases such as diabetes, obesity, arteriosclerosis, and dementia by reacting with proteins, carbohydrates, lipids, and DNA to damage cells of various tissues (Kim et al., 2008).
항산화 물질은 체내 생성 활성산소에 의한 동맥경화, 암 및 염증의 예방과 감소에 기여하는 것으로 알려지고 있다. 이에 활성산소를 조절하거나 제거하는 능력을 지닌 생리활성물질에 대한 연구의 필요성이 대두되면서 천연물을 이용한 바이오 건강 소재 개발 연구가 활발히 진행되고 있다(Seo et al. 2011).Antioxidants are known to contribute to the prevention and reduction of arteriosclerosis, cancer and inflammation caused by free radicals produced in the body. Accordingly, as the need for research on physiologically active substances with the ability to control or remove free radicals has emerged, research on the development of bio-health materials using natural products is being actively conducted (Seo et al. 2011).
여러 원인들에 의해 발병하는 성인병 질환들은 염증성 질환의 성격을 많이 가지고 있다. 염증은 세균 감염, 화학물질 등에 대해 생체가 재생이나 회복 등을 하기 위한 방어적 반응으로 나타내는 증세이다(Kawamata et al. 2000). 이 과정에서 활성산소 nitric oxide (NO)는 외부 균감염이나 cytokines 등에 의해 대식세포와 같은 면역세포에 의해 생성되어 각종 생리 및 병리적 과정에 있어 중요한 역할을 한다(Aktan 2004). 하지만 과도하게 생성된 NO는 체내 부작용을 일으켜 염증반응을 과도하게 촉진시킬 뿐만 아니라 지속적인 만성염증 반응은 인체조직의 손상 및 유전자 변이 등을 촉진시켜, 관절염, 동맥경화 및 암 등을 일으킨다고 보고되고 있다(Liao et al. 2011). Geriatric diseases caused by various causes have many characteristics of inflammatory diseases. Inflammation is a symptom expressed as a defensive reaction for the body to regenerate or recover against bacterial infection or chemicals (Kawamata et al. 2000). In this process, reactive oxygen species nitric oxide (NO) is generated by immune cells such as macrophages by external fungal infection or cytokines, and plays an important role in various physiological and pathological processes (Aktan 2004). However, it is reported that excessively generated NO causes side effects in the body and excessively promotes the inflammatory response, and the continuous chronic inflammatory response promotes damage to human tissues and genetic mutations, causing arthritis, arteriosclerosis and cancer. (Liao et al. 2011).
최근에 개발된 염증성 질환을 치료하는 항염증 면역활성제로 사용되는 약제는 신장염, 위염, 심장질환 등을 초래함으로써 인체 안전성 측면에서 문제점을 안고 있어, 보다 안전한 맞춤형 항염증 면역활성 치료후보제 소재를 식물 천연물에서 찾는 연구가 활발하게 이루어지고 있다(Dogne et al. 2006).The recently developed drug used as an anti-inflammatory immunoactive agent to treat inflammatory diseases has problems in terms of human safety by causing nephritis, gastritis, heart disease, etc. Research to find natural products is being actively conducted (Dogne et al. 2006).
한편, 활성산소(oxygen radical)는 생체의 가장 기본 성분인 단백질, 지방, 핵산 등을 무차별 파괴시킴으로써 인체의 주요 세포들 특히 근육세포, 면역세포와 같은 여러 조직의 세포들의 기능을 상실케 하여 노화를 야기 시키고, 동시에 근감소증, 관절염, 골다공증 등 여러 주요 노인성 질병들을 발생시킨다. 특히 노화과정에서 말초 조직에는 저산소증이 쉽게 발생하고, 이것이 말초 조직의 미토콘드리아에서 ATP의 생성을 저하시킨다. 따라서, ATP 생성 저하로 인해 세포의 기능이 잘 유지되지 못하게 되고, 결국 세포사가 발생하며, 죽은 세포를 제거하기 위해 염증세포들이 모여들게 된다. 또한 상기 염증세포들이 분비하는 염증 매개 물질들에 의해 미세염증이 유발되고 이 염증들이 축적되면서 노화현상이 더욱 더 촉진된다. On the other hand, oxygen radicals indiscriminately destroy the most basic components of the body, such as proteins, fats, and nucleic acids, thereby causing the loss of functions of the main cells of the human body, especially the cells of various tissues, such as muscle cells and immune cells, thereby preventing aging. At the same time, it causes several major geriatric diseases such as sarcopenia, arthritis, and osteoporosis. In particular, during the aging process, hypoxia easily occurs in peripheral tissues, which lowers ATP production in the mitochondria of peripheral tissues. Therefore, due to the decrease in ATP production, the function of the cells is not maintained well, eventually cell death occurs, and the inflammatory cells gather to remove the dead cells. In addition, microinflammation is induced by the inflammatory mediators secreted by the inflammatory cells, and as these inflammations accumulate, the aging phenomenon is further accelerated.
그러므로, 의료복지 비용절감의 측면에서, 노화 및 근감소증 등 노인성질환을 감소시키는 방안으로, 항산화 효능과 항염증 효능을 동시에 가지며, 인체에 안전한 새로운 기능성 소재의 탐색 및 개발이 요구되고 있다.Therefore, in terms of medical welfare cost reduction, as a method of reducing geriatric diseases such as aging and sarcopenia, it is required to search and develop new functional materials that have antioxidant and anti-inflammatory effects at the same time and are safe for the human body.
본 발명은 항염증 면역활성 및 항산화능이 우수한 식물 추출물을 포함함으로써, 인체에 안전하며 우수한 항염증 면역활성 및 항산화 효능을 갖는 화장료 조성물, 약학적 조성물, 및 식품 조성물을 제공하는 것을 목적으로 한다. An object of the present invention is to provide a cosmetic composition, a pharmaceutical composition, and a food composition, which are safe for the human body and have excellent anti-inflammatory immune activity and antioxidant efficacy, by including a plant extract having excellent anti-inflammatory immune activity and antioxidant activity.
특히, 우수한 항염증 면역활성 및 항산화 효능으로 인하여 노인의 근력 또는 근육 강화를 위한 근세포 조성에 우수한 효과를 제공하는 약학적 조성물 및 식품 조성물을 제공하는 것을 목적으로 한다. In particular, an object of the present invention is to provide a pharmaceutical composition and a food composition that provide an excellent effect on the composition of muscle cells for muscle strength or muscle strengthening in the elderly due to excellent anti-inflammatory immune activity and antioxidant efficacy.
본 발명은 the present invention
프테로카리아 스테놉테라(Pterocarya stenoptera C. DC.) 에탄올 추출물을 포함하는 항염증 면역활성 및 항산화 활성을 갖는 화장료 조성물을 제공한다.Pterocaria stenoptera stenoptera C. DC .) It provides a cosmetic composition having anti-inflammatory immune activity and antioxidant activity comprising an ethanol extract.
또한 본 발명은 Also, the present invention
프테로카리아 스테놉테라(Pterocarya stenoptera C. DC.) 에탄올 추출물을 포함하는 염증성 질환 또는 활성산소로 인해 발생하는 질환의 예방 및 치료용 약학적 조성물을 제공한다.Pterocaria stenoptera stenoptera C. DC .) Provides a pharmaceutical composition for preventing and treating inflammatory diseases or diseases caused by free radicals, including an ethanol extract.
또한 본 발명은 Also, the present invention
프테로카리아 스테놉테라(Pterocarya stenoptera C. DC.) 에탄올 추출물을 포함하는 항염증 면역활성 및 항산화 활성을 갖는 식품 조성물을 제공한다.Pterocaria stenoptera stenoptera C. DC .) It provides a food composition having anti-inflammatory immune activity and antioxidant activity comprising an ethanol extract.
본 발명의 화장료 조성물, 약학적 조성물, 및 식품 조성물은 식물 성분인프테로카리아 스테놉테라(Pterocarya stenoptera C. DC.) 에탄올 추출물을 포함함으로써 인체에 안전하며, 우수한 항염증 면역활성 및 항산화 활성을 제공한다. The cosmetic composition, pharmaceutical composition, and food composition of the present invention is a plant component Pterocarya stenoptera (Pterocarya) stenoptera C. DC .) It is safe to the human body by including ethanol extract, and provides excellent anti-inflammatory and immune activity and antioxidant activity.
특히, 본 발명의 약학적 조성물 및 식품 조성물은 우수한 항염증 면역활성 및 항산화 효능으로 인하여 노인의 근력 또는 근육 강화를 위한 근세포 조성에 우수한 효과를 제공한다.In particular, the pharmaceutical and food compositions of the present invention provide an excellent effect on the composition of muscle cells for strengthening or strengthening muscles in the elderly due to their excellent anti-inflammatory immune activity and antioxidant efficacy.
도 1 내지 3은 실험예 1에서 실시된 항산화 효능 테스트 결과를 나타낸 그래프이며,
도 4 내지 6은 실험예 2에서 실시된 항염증 면역활성 효능 테스트 결과를 나타낸 그래프이며,
도 7 내지 9는 실험예 3에서 실시된 세포 독성 테스트 결과를 나타낸 그래프이다.1 to 3 are graphs showing the results of the antioxidant efficacy test conducted in Experimental Example 1,
4 to 6 are graphs showing the results of the anti-inflammatory immune activity efficacy test carried out in Experimental Example 2,
7 to 9 are graphs showing the results of the cytotoxicity test carried out in Experimental Example 3.
이하에서 본 발명을 자세하게 설명한다. Hereinafter, the present invention will be described in detail.
본 발명은 프테로카리아 스테놉테라(Pterocarya stenoptera C. DC.) 에탄올 추출물을 포함하는 항염증 면역활성 및 항산화 활성을 갖는 조성물을 제공한다.The present invention is Pterocarya stenoptera (Pterocarya) stenoptera C. DC .) provides a composition having anti-inflammatory immune activity and antioxidant activity comprising an ethanol extract.
상기 조성물은 항염증 면역활성 및 항산화 활성을 갖는 화장료 조성물, 염증성 질환 또는 활성산소로 인해 발생하는 질환의 예방 및 치료용 약학적 조성물, 항염증 면역활성 및 항산화 활성을 갖는 식품 조성물일 수 있다.The composition may be a cosmetic composition having anti-inflammatory immune activity and antioxidant activity, a pharmaceutical composition for preventing and treating inflammatory diseases or diseases caused by free radicals, and a food composition having anti-inflammatory immune activity and antioxidant activity.
상기 조성물은 가르시니아 코와(Garcinia cowa Roxb .) 에탄올 추출물 및 나제이아 플루리(Nageia fleuryi ( Hickel ) de Laub) 에탄올 추출물 중에서 선택되는 1종 이상의 성분을 더 포함할 수 있다.The composition is Garcinia Kowa ( Garcinia cowa Roxb . ) Ethanol extract and Nageia fluri fleuryi ( Hickel ) de Laub ) may further include one or more components selected from the ethanol extract.
프테로카리아 스테놉테라(Pterocarya stenoptera C. DC.)는 쌍떡잎 식물 가래나무목 가래나무과의 낙엽교목으로 개굴피나무속 중국굴피나무로 열매가 열린다. 영문으론 Chinese Wingnut으로 불린다. Pterocaria stenoptera stenoptera C. DC .) is a dicotyledonous plant, a deciduous tree in the family Acetaceae, which bears fruit as a Chinese cypress in the genus A. In English, it is called Chinese Wingnut.
상기 가르시니아 코와(Garcinia cowa Roxb .)는 동남아지역 자생하는 열대식물로 체내 지방 생성을 억제해 체중감량을 유도하거나 뇌에서 세로토닌 분비를 증가시켜 식욕을 억제하는 기능 성분(HCA; hydroxycitric acid)이 껍질에 들어있다고 알려져 있다. The Garcinia Kowa ( Garcinia cowa Roxb . ) is a tropical plant that is native to Southeast Asia and is known to contain a functional ingredient (HCA; hydroxycitric acid) that suppresses body fat production to induce weight loss or suppress appetite by increasing serotonin secretion in the brain.
상기 나제이아 플루리(Nageia fleuryi ( Hickel ) de Laub)는 중국남부, 캄보디아, 라오스, 베트남 등 동남아 지역 자생하는 식물이다.The Nageia fleuryi ( Nageia fleuryi ( Hickel ) de Laub ) is a plant native to Southeast Asia, such as southern China, Cambodia, Laos, and Vietnam.
하기 실험예의 DPPH 분석에 따르면, 상기 프테로카리아 스테놉테라의 에탄올 추출물은 비타민 C 대조군에 비해 33.53% 더 높은 활성 산소 억제 활성을 가질 수 있다. 가르시니아 코와와 나제이아 플루리 에탄올추출물은 비타민 C 대조군보다는 낮지만 활성 산소 억제 활성을 나타낸다. According to the DPPH analysis of the following experimental example, the ethanol extract of Pterocaria stenoptera may have 33.53% higher active oxygen inhibitory activity than the vitamin C control. Garcinia cowa and Nazeia puri ethanol extracts showed reactive oxygen inhibitory activity, although lower than the vitamin C control group.
또한, 하기 실험예의 항염증 면역활성 측정을 위해 생성 산화질소를 분석한 결과에 따르면, 프테로카리아 스테놉테라, 가르시니아 코와 및 나제이아 플루리 에탄올 추출물은 LPS 대조군과 비교하여 각각 19.9%, 16.06% 및 48.70% 더 많은 항염증 면역활성을 나타낸다.In addition, according to the result of analyzing the nitric oxide generated for measuring the anti-inflammatory immune activity of the following experimental example, the ethanol extracts of Pterocaria stenoptera, Garcinia cowa and Nazeia fluri were each 19.9% compared to the LPS control. , 16.06% and 48.70% more anti-inflammatory immune activity.
또한, 하기 실험예의 세포 독성을 결정하기 위한 MTT 분석 결과에 의하면, 프테로카리아 스테놉테라 및 가르시니아 코와 에탄올 추출물은 LPS 대조군과 비교하여 2.60%, 4.60% 강한 세포 독성을 보이며, 나제이아 플루리의 에탄올 추출물은 LPS 대조군에 비해 29.30% 더 강한 세포 독성을 나타낸다. 그러나, 이들 추출물을 사용하는 데에는 문제가 없는 것으로 확인된다.In addition, according to the MTT analysis results for determining the cytotoxicity of the following experimental examples, the ethanol extracts of Pterocaria stenoptera and Garcinia cowa showed 2.60%, 4.60% strong cytotoxicity compared to the LPS control, Nazeia The ethanol extract of fluri showed 29.30% stronger cytotoxicity compared to the LPS control. However, it is confirmed that there is no problem in using these extracts.
상기와 같은 결과에 따르면, 프테로카리아 스테놉테라 에탄올 추출물이 상당히 우수한 활성산소억제활성을 가지며, 비교적 낮은 세포 독성을 가지고 있음을 나타낸다. 따라서 프테로카리아 스테놉테라가 에탄올 추출물은 항염증 면역활성을 갖는 잠재적 항산화제 치료제로 사용될 수 있을 것으로 보인다.According to the results as described above, it is indicated that the ethanol extract of Pterocaria stenoptera has a very good reactive oxygen species inhibitory activity and has relatively low cytotoxicity. Therefore, the ethanol extract of Pterocaria stenoptera may be used as a potential antioxidant treatment with anti-inflammatory and immune activity.
상기 프테로카리아 스테놉테라 에탄올 추출물은 프테로카리아 스테놉테라 잎 을 에탄올에 넣고 섭씨 25도에서 15시간 동안 추출한 후, 에탄올을 증발시켜서 분말 형태로 제조할 수 있다. The Pterocaria stenoptera ethanol extract is Pterocaria stenoptera leaves It can be prepared in powder form by putting it in ethanol and extracting it at 25 degrees Celsius for 15 hours, then evaporating the ethanol.
상기 가르시니아 코와 에탄올 추출물은 가르시니아 코와 잎을 에탄올에 넣고 섭씨 25도에서 15시간 동안 추출한 후, 에탄올을 증발시켜서 분말 형태로 제조할 수 있다. The Garcinia nose and ethanol extract can be prepared in powder form by putting Garcinia nose and leaves in ethanol and extracting it at 25 degrees Celsius for 15 hours, then evaporating the ethanol.
상기 나제이아 플루리 에탄올 추출물은 나제이아 플루리 잎을 에탄올에 넣고 섭씨 25도에서 15시간 동안 추출한 후, 에탄올을 증발시켜서 분말 형태로 제조할 수 있다. The Nazeia fluri ethanol extract can be prepared in powder form by putting the Nazeia fluri leaf into ethanol and extracting it at 25 degrees Celsius for 15 hours, then evaporating the ethanol.
본 발명에서 상기 에탄올의 농도는 특별히 한정되지 않으나, 바람직하게 20 내지 80%(w/w), 더욱 바람직하게 70%(w/w) 에탄올 수용액이 사용될 수 있다. In the present invention, the concentration of ethanol is not particularly limited, but preferably 20 to 80% (w/w), more preferably 70% (w/w) aqueous ethanol solution may be used.
상기에서 프테로카리아 스테놉테라 에탄올 추출물과, 가르시니아 코와 에탄올 추출물 및 나제이아 플루리 에탄올 추출물 중에서 선택되는 1종 이상은 1~3 : 1~3의 중량비로 포함될 수 있으며, In the above, at least one selected from the Pterocaria stenoptera ethanol extract, the Garcinia cowa ethanol extract, and the Nazeia fluri ethanol extract may be included in a weight ratio of 1-3: 1 to 3,
상기 가르시니아 코와 에탄올 추출물 및 나제이아 플루리 에탄올 추출물이 모두 포함되는 경우, 이들은 3:7 내지 7:3의 중량비로 포함될 수 있다. When both the Garcinia cowa ethanol extract and the Nazeia fluri ethanol extract are included, they may be included in a weight ratio of 3:7 to 7:3.
상기 프테로카리아 스테놉테라(Pterocarya stenoptera C. DC.) 에탄올 추출물은 10 내지 20 %(w/v) 농도로 사용되는 것이 바람직할 수 있다. The Pterocaria stenoptera (Pterocarya) stenoptera C. DC .) It may be preferable to use the ethanol extract at a concentration of 10 to 20% (w/v).
본 발명의 화장료 조성물은 일반적인 유화 제형 및 가용화 제형의 형태로 제조될 수 있다. 상기 유화 제형으로는 영양화장수, 크림, 에센스 등을 들 수 있으며, 상기 가용화 제형으로는 유연화장수 등을 들 수 있다. The cosmetic composition of the present invention may be prepared in the form of general emulsified formulations and solubilized formulations. The emulsified formulation may include nutrient lotion, cream, essence, and the like, and the solubilized formulation may include softened lotion and the like.
상기 화장료 조성물의 적합한 제형은 용액, 겔, 고체 또는 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는 이온형(리포좀), 비이온형의 소낭 분산제의 형태, 크림, 스킨, 로션, 파우더, 연고, 스프레이 또는 콘실 스틱, 또한, 포말(foam)의 형태 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태일 수 있으나, 이에 제한되는 것 아니다.Suitable formulations of the cosmetic composition include solutions, gels, solid or kneaded dry products, emulsions obtained by dispersing an oil phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes), nonionic vesicular dispersants. It may be in the form of a cream, skin, lotion, powder, ointment, spray or cone stick, and also in the form of a foam or an aerosol composition further containing a compressed propellant, but is not limited thereto.
상기 화장료 조성물은 추가적으로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제, 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제, 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장료 조성물에 통상적으로 사용되는 임의의 다른 성분과 같은 통상적으로 사용되는 보조제를 함유할 수 있다.The cosmetic composition may additionally contain fatty substances, organic solvents, solubilizers, thickeners and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metals Commonly used adjuvants such as sequestering agents, chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any other ingredient commonly used in cosmetic compositions may contain.
본 발명의 약학적 조성물은 항염증 면역활성 효과 및 활성산소를 제거하는 항산화 효과를 갖기 때문에, 염증성 질환들 또는 활성산소로 인해 발생하는 질환들의 예방, 개선 및 치료에 사용될 수 있다. Since the pharmaceutical composition of the present invention has an anti-inflammatory immunoactive effect and an antioxidant effect of removing free radicals, it can be used for prevention, improvement and treatment of inflammatory diseases or diseases caused by free radicals.
상기 염증성 질환은 염증을 주병변으로 하는 질병을 총칭하는 의미로서, 이에 제한되지는 않으나, 알러지성 천식, 알러지성 비염, 알러지성 점막염, 두드러기 및 아나필락스(anaphylax)를 포함하는 알러지성 질환, 경피증(systemic sclerosis), 피부근염(dermatomyositis) 및 포함체 근육염(inclusion body myositis)을 포함하는 근병증, 관절염, 아토피성 피부염, 건선, 천식, 다발성 경화증, ssRNA 및 dsRNA 바이러스 감염증, 패혈증, 다발성 연골염, 경피증, 습진, 통풍, 치주질환, 베체트 증후군, 부종, 맥관염, 가와사키병, 당뇨병성 망막염, 자가 면역 췌장염, 혈관염, 사구체 신염, 급성 및 만성 기관지염, 및 인플루엔자 감염증일 수 있다.The inflammatory disease is a generic term for diseases with inflammation as the main lesion, and is not limited thereto, but allergic diseases including, but not limited to, allergic asthma, allergic rhinitis, allergic mucositis, urticaria and anaphylax; Myopathy including systemic sclerosis, dermatomyositis and inclusion body myositis, arthritis, atopic dermatitis, psoriasis, asthma, multiple sclerosis, ssRNA and dsRNA virus infection, sepsis, polychondritis, scleroderma , eczema, gout, periodontal disease, Behcet's syndrome, edema, vasculitis, Kawasaki disease, diabetic retinitis, autoimmune pancreatitis, vasculitis, glomerulonephritis, acute and chronic bronchitis, and influenza infection.
상기 활성산소로 인해 발생하는 질환은 이에 제한되지는 않으나, 동맥경화증, 루게릭병, 파킨슨병, 알츠하이머, 근위축색경화증 및 헌팅톤병을 포함하는 퇴행성 신경질환, 심근경색, 협심증, 관상동맥질환, 허혈성 심장질환을 포함하는 심혈관 질환, 뇌졸중을 포함하는 허혈성 뇌질환, 노화 등 다양한 질환을 포함할 수 있으며, 구체적으로 활성산소에 의해 발생되는 노화일 수 있다.Diseases caused by free radicals are not limited thereto, but degenerative neurological diseases including arteriosclerosis, Lou Gehrig's disease, Parkinson's disease, Alzheimer's, amyotrophic sclerosis and Huntington's disease, myocardial infarction, angina pectoris, coronary artery disease, ischemic heart It may include various diseases such as cardiovascular disease including diseases, ischemic brain disease including stroke, and aging, and specifically aging caused by free radicals.
상기 본 발명의 약학조성물은 약학적으로 허용가능한 담체를 추가로 포함할 수 있다. 본 발명의 용어 "약학적으로 허용가능한"이란 상기 조성물에 노출되는 세포나 인간에게 독성이 없는 특성을 나타내는 것을 의미한다. 상기 담체는 완충제, 보존제, 무통화제, 가용화제, 등장제, 안정화제, 기제, 부형제, 윤활제 등 당업계에 공지된 것이라면 제한없이 사용할 수 있다.The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier. As used herein, the term “pharmaceutically acceptable” refers to exhibiting non-toxic properties to cells or humans exposed to the composition. The carrier may be used without limitation as long as it is known in the art, such as buffers, preservatives, pain relievers, solubilizers, isotonic agents, stabilizers, bases, excipients, lubricants, and the like.
또한, 본 발명의 약학조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 나아가, 연고제, 로션제, 스프레이제, 패취제, 크림제, 산제, 현탁제, 겔제 또는 젤의 형태의 피부 외용제의 형태로 사용될 수 있다. In addition, the pharmaceutical composition of the present invention may be formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions according to conventional methods, respectively. can Furthermore, it may be used in the form of an ointment, lotion, spray, patch, cream, powder, suspension, gel, or external preparation for skin in the form of a gel.
본 발명의 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.Carriers, excipients and diluents that may be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, it is prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 프테로카리아 스테놉테라 에탄올 추출물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트, 탈크 같은 윤활제들도 사용된다. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the ethanol extract of Pterocaria stenoptera, for example, starch, calcium carbonate. It is prepared by mixing (calcium carbonate), sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. Liquid formulations for oral use include suspensions, solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients, for example, wetting agents, sweeteners, fragrances, preservatives, etc. may be included. .
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, etc. can be used.
본 발명의 약학적 조성물은 약학적으로 유효한 양으로 투여한다. 본 발명의 용어 "투여"란, 적절한 방법으로 개체에게 소정의 물질을 도입하는 것을 의미하며 상기 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 투여될 수 있다. 복강내 투여, 정맥내 투여, 근육내 투여, 피하 투여, 피내 투여, 경구 투여, 국소 투여, 비내 투여, 폐내 투여, 직장내 투여될 수 있으나, 이에 제한되지는 않는다.The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. As used herein, the term "administration" means introducing a predetermined substance to an individual by an appropriate method, and the administration route of the composition may be administered through any general route as long as it can reach a target tissue. Intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, may be administered intrarectally, but is not limited thereto.
상기 용어 "개체"란 는 인간을 포함한 쥐, 생쥐, 가축 등의 모든 동물을 의미한다. 바람직하게는, 인간을 포함한 포유동물일 수 있다.The term “individual” refers to all animals including humans, mice, mice, and livestock. Preferably, it may be a mammal including a human.
상기 용어 "약학적으로 유효한 양"이란 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분하며 부작용을 일으키지 않을 정도의 양을 의미하며, 유효 용량 수준은 환자의 성별, 연령, 체중, 건강상태, 질병의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 방법, 투여 시간, 투여 경로, 및 배출 비율, 치료 기간, 배합 또는 동시에 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 당업자에 의해 용이하게 결정될 수 있다. 투여는 상기 권장 투여량을 하루에 한 번 투여할 수도 있고, 수회 나누어 투여할 수도 있다.The term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment and not to cause side effects, and the effective dose level is determined by the patient's gender, age, and weight. , health condition, disease type, severity, drug activity, sensitivity to drug, administration method, administration time, administration route, and excretion rate, treatment period, factors including drugs used in combination or concomitantly, and other medical fields. It can be readily determined by one of ordinary skill in the art according to known factors. For administration, the recommended dosage may be administered once a day, or divided into several administrations.
본 발명의 식품 조성물은 상기 프테로카리아 스테놉테라 에탄올 추출물을 그대로 사용하거나 다른 식품 또는 식품 성분과 함께 사용하여, 통상의 방법에 따라 적절하게 제조될 수 있다. 유효 성분의 혼합양은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있으며, 식품학적으로 허용가능한 식품 보조 첨가제를 추가로 포함할 수 있다. 본 발명의 조성물은 천연물로부터 유래한 추출물을 유효성분으로 하므로 안정성 면에서 문제가 없기 때문에 혼합량에 큰 제한은 없다.The food composition of the present invention may be suitably prepared according to a conventional method by using the Pterocaria stenoptera ethanol extract as it is or in combination with other foods or food ingredients. The mixing amount of the active ingredient may be suitably determined according to the purpose of use (prevention, health or therapeutic treatment), and may further include a food pharmaceutically acceptable food supplement additive. Since the composition of the present invention uses an extract derived from a natural product as an active ingredient, there is no problem in terms of stability, so there is no great limitation on the amount of mixing.
본 발명의 식품 조성물은 통상적인 의미의 식품을 모두 포함할 수 있으며, 기능성 식품, 건강기능식품 등 당업계에 알려진 용어와 혼용 가능하다.The food composition of the present invention may include all foods in a conventional sense, and may be used interchangeably with terms known in the art, such as functional food and health functional food.
본 발명의 용어 "기능성 식품"은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.As used herein, the term "functional food" refers to food manufactured and processed using raw materials or ingredients useful for the human body according to Health Functional Food Act No. 6727, and "functionality" refers to the structure of the human body. And it means ingestion for the purpose of obtaining useful effects for health purposes such as regulating nutrients for function or physiological action.
또한, 본 발명의 용어 "건강기능식품"은 건강보조의 목적으로 특정성분을 원료로 하거나 식품 원료에 들어있는 특정성분을 추출, 농축, 정제, 혼합 등의 방법으로 제조, 가공한 식품을 말하며, 상기 성분에 의해 생체방어, 생체리듬의 조절, 질병의 방지와 회복 등 생체조절기능을 생체에 대하여 충분히 발휘할 수 있도록 설계되고 가공된 식품을 말하는 것으로서, 상기 건강식품용 조성물은 질병의 예방 및 질병의 회복 등과 관련된 기능을 수행할 수 있다.In addition, the term "health functional food" as used in the present invention refers to a food manufactured and processed using a specific ingredient as a raw material or by extracting, concentrating, refining, or mixing a specific ingredient contained in the food raw material for the purpose of health supplementation, It refers to a food designed and processed to sufficiently exert biological control functions such as biological defense, regulation of biological rhythm, prevention and recovery of disease, etc., by the above ingredients, and the composition for health food is used for prevention of diseases and prevention of diseases. It can perform functions related to recovery, etc.
본 발명의 식품 조성물이 사용될 수 있는 식품의 종류에는 제한이 없다. 아울러 본 발명의 식품 조성물에는 당업자의 선택에 따라 식품에 함유될 수 있는 적절한 기타 보조 성분과 공지의 첨가제가 포함될 수 있다. There is no limitation on the kind of food in which the food composition of the present invention can be used. In addition, the food composition of the present invention may include other suitable auxiliary ingredients and known additives that may be contained in food according to the selection of those skilled in the art.
상기 보조 성분의 예로는 육류, 소세지, 빵, 초콜렛, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림 류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있다.Examples of the auxiliary ingredients include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes etc.
또한, 본 발명에 적용될 수 있는 식품에는 예컨대, 특수영양식품(예: 노인 영양식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류(예: 라면류, 국수류 등), 건강보조식품, 조미식품(예: 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류(예:스낵류), 유가공품(예: 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품(각종 김치류, 장아찌 등), 음료(예: 과실, 채소류 음료, 두유류, 발효음료류 등), 천연조미료(예, 라면스프 등) 등 모든 식품을 포함할 수 있다.In addition, foods that can be applied to the present invention include, for example, special nutritional foods (eg, nutritional food for the elderly), processed meat products, fish meat products, tofu, jelly, noodles (eg, ramen, noodles, etc.), health supplements, seasoned foods ( Ex: soy sauce, soybean paste, red pepper paste, mixed soy sauce, etc.), sauces, sweets (e.g. snacks), dairy products (e.g. fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various kimchi, pickles, etc.), drinks ( Example: It can include all foods such as fruit, vegetable beverages, soy milk, fermented beverages, etc.) and natural seasonings (eg, ramen soup, etc.).
본 발명의 건강기능식품 조성물이 음료의 형태로 사용될 경우에는 통상의 음료와 같이 여러 가지 감미제, 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 외에 본 발명의 건강기능식품 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.When the health functional food composition of the present invention is used in the form of a beverage, it may contain various sweetening agents, flavoring agents, or natural carbohydrates as additional ingredients, as in a conventional beverage. In addition to the above, the health functional food composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin , alcohol, a carbonation agent used in carbonated beverages, and the like. In addition, it may contain the pulp for the production of natural fruit juice, fruit juice beverage and vegetable beverage.
이하에서, 제조예 및 실시예를 통하여 본 발명을 보다 상세히 설명한다. 그러나, 하기의 실시예는 본 발명을 더욱 구체적으로 설명하기 위한 것으로서, 본 발명의 범위가 하기의 실시예에 의하여 한정되는 것은 아니다. 하기의 실시예는 본 발명의 범위 내에서 당업자에 의해 적절히 수정, 변경될 수 있다.Hereinafter, the present invention will be described in more detail through Preparation Examples and Examples. However, the following examples are provided to explain the present invention in more detail, and the scope of the present invention is not limited by the following examples. The following examples can be appropriately modified and changed by those skilled in the art within the scope of the present invention.
[[ 실시예Example ]]
(1) 시료 (1) sample
아열대 지방 원산지인 식물 프테로카리아 스테놉테라(Pterocarya stenoptera C. DC.), 가르시니아 코와(Garcinia cowa Roxb .) 및 나제이아 플루리(Nageia fleuryi ( Hickel ) de Laub .)는 한국생명공학연구원(KRIBB) 바이오의약인프라사업부 해외생물소재센터(IBMRC)로부터 구했다. Pterocarya stenoptera , a plant native to the subtropics stenoptera C. DC. ) , Garcinia Kowa cowa Roxb . ) and Nageia fleuryi ( Hickel ) de Laub .) were obtained from the International Biomaterials Center (IBMRC) of the Biomedical Infrastructure Division of the Korea Research Institute of Bioscience and Biotechnology (KRIBB).
(2) 세포배양 (2) cell culture
Mouse 대식세포 RAW 264.7는 한국세포주연구재단 한국세포주은행로부터 구하였다. 배지 DMEM, 10% 혈청, 10 mg/L 페니실린, 글루타맥스, 히피스(HEPES) 버퍼(GIBCO, U.S.)를 이용하여, 섭씨 37도, 5% 탄산가스 배양기를 사용하여 세포를 배양하였다. 세포 안전성을 측정하기위해, SIGMA에서 MTT를 구하였고, DMSO와 Griess 시약도 SIGMA에서 구입하였다. Mouse macrophage RAW 264.7 was obtained from the Korea Cell Line Research Foundation, Korea Cell Line Bank. The cells were cultured using a medium DMEM, 10% serum, 10 mg/L penicillin, glutamax, and HEPES buffer (GIBCO, U.S.) at 37°C and a 5% carbon dioxide gas incubator. To measure cell safety, MTT was obtained from SIGMA, and DMSO and Griess reagent were also purchased from SIGMA.
(3) 통계처리 (3) Statistical processing
하기 실험은 각각 세 번 반복해서 처리했고, EXCEL 2013 이용해 통계분석을 수행하였다(p값 < 0.05).Each of the following experiments was repeated three times, and statistical analysis was performed using EXCEL 2013 (p value <0.05).
실시예Example 1: One: 프테로카리아pterocaria 스테놉테라stenoptera 추출물 제조 extract preparation
프테로카리아 스테놉테라( Pterocarya stenoptera C. DC) 잎 20g을 70% 에탄올 수용액에 넣고, 섭씨 25도에서 15시간 동안 추출한 후, 감압하에 에탄올을 증발시켜서 분말형태의 프테로카리아 스테놉테라 추출물을 제조하였다. Pterocaria stenoptera stenoptera C. DC) leaves were put in a 70% aqueous ethanol solution, extracted at 25 degrees Celsius for 15 hours, and then the ethanol was evaporated under reduced pressure to prepare a powdery Pterocaria stenoptera extract.
실시예Example 2: 2: 가르시니아Garcinia 코와 추출물 제조 Preparation of nose and extract
가르시니아 코와(Garcinia cowa Roxb .) 잎 20g을 70% 에탄올 수용액에 넣고, 섭씨 25도에서 15시간 동안 추출한 후, 감압하에 에탄올을 증발시켜서 분말형태의 가르시니아 코와 추출물을 제조하였다. Garcinia Kowa cowa Roxb . ) 20 g of leaves were placed in a 70% aqueous ethanol solution, extracted at 25 degrees Celsius for 15 hours, and then the ethanol was evaporated under reduced pressure to prepare a powdery Garcinia cowa extract.
실시예Example 3: 3: 나제이아nazeia 플루리flurry 추출물 제조 extract preparation
나제이아 플루리(Nageia fleuryi ( Hickel ) de Laub) 잎 20g을 70% 에탄올 수용액에 넣고, 섭씨 25도에서 15시간 동안 추출한 후, 감압하에 에탄올을 증발시켜서 분말형태의 나제이아 플루리 추출물을 제조하였다. Nageia Flurry fleuryi ( Hickel ) de Laub ) 20 g of the leaves were placed in a 70% aqueous ethanol solution, extracted at 25 degrees Celsius for 15 hours, and then the ethanol was evaporated under reduced pressure to prepare a powdery Nazeia puri extract.
실험예Experimental example 1: 항산화 효능 테스트 1: Antioxidant efficacy test
(1) 실험방법(1) Experimental method
항산화 효능 검사를 위해 DPPH를 시그마에서 구입했고, 상기 실시예 1 내지 3에서 제조된 각각의 식물 추출물을 에탄올 용매에 녹여 각각 3, 5, 8, 10, 15, 20, 23, 및 25%(w/v) 농도의 시료를 제조하였다. 상기 시료 100 μl와 DPPH 시약 용액 100 μl(농도 0.2 mM)를 96 well 플레이트에서 혼합했다. 섭씨 37도에서 30분간 반응시킨 후, 517 nm에서 ELISA 기기로 흡광도를 측정했다(Epoch, Biotek, U.S.). 비타민C(500 μg/ml) 100 μl와 DPPH 용액(0.2 mM) 100 μl를 혼합해서 표준용액을 만들었다. 메탄올 100 μl와 DPPH 용액(0.2 mM) 100 μl를 blank 표준용액으로 사용하였다. 라디칼저해율(%)은 아래와 같은 수학식을 이용하였다.DPPH was purchased from Sigma for the antioxidant efficacy test, and each of the plant extracts prepared in Examples 1 to 3 was dissolved in an ethanol solvent to 3, 5, 8, 10, 15, 20, 23, and 25% (w /v) concentration samples were prepared. 100 μl of the sample and 100 μl of the DPPH reagent solution (concentration 0.2 mM) were mixed in a 96-well plate. After reacting at 37 degrees Celsius for 30 minutes, absorbance was measured at 517 nm with an ELISA device (Epoch, Biotek, U.S.). A standard solution was prepared by mixing 100 μl of vitamin C (500 μg/ml) and 100 μl of DPPH solution (0.2 mM). 100 μl of methanol and 100 μl of DPPH solution (0.2 mM) were used as blank standard solutions. The radical inhibition rate (%) was calculated using the following equation.
[수학식][Equation]
라디칼 저해율(%) = [(표준물질 흡광 - 샘플 흡광) / (표준물질 흡광)] X 100 Radical inhibition rate (%) = [(standard material absorption - sample absorption) / (standard material absorption)]
(샘플 흡광 = DPPH 흡광 - 메탄올 흡광)(Sample Absorption = DPPH Absorption - Methanol Absorption)
(2) 실험결과(2) Experiment result
상기 DPPH 항산화 활성을 테스트한 결과를 도 1 내지 도 3에 나타내었다. 도 1은 상기 실시예 1 내지 3에서 제조된 각각의 식물 추출물 각각 10%(w/v) 농도의 시료 100 μl를 사용한 결과를 나타냈으며, 도 2에는 실시예 1의 프테로카리아 스테놉테라(Pterocarya stenoptera C. DC.) 에탄올 추출물 3 내지 25%(w/v) 농도의 시료 100 μl를 사용한 결과를 나타냈으며, 도 3에는 실시예 3의 나제이아 플루리(Nageia fleuryi ( Hickel ) de Laub) 에탄올 추출물 3 내지 25%(w/v) 농도의 시료 100 μl를 사용한 결과를 나타었다. The results of testing the DPPH antioxidant activity are shown in FIGS. 1 to 3 . 1 shows the results of using 100 μl of each of the plant extracts prepared in Examples 1 to 3 at a concentration of 10% (w/v), respectively, and FIG. 2 shows Pterocaria stenoptera of Example 1. ( Pterocarya stenoptera C. DC .)
도 1에서 확인되는 바와 같이, 비타민C 표준물질과 비교하여, 실시예 1의 프테로카리아 스테놉테라(Pterocarya stenoptera C. DC.) 에탄올 추출물은 32.0% 더 우수한 항산화능을 나타냈다. 실시예 2의 가르시니아 코와(Garcinia cowa Roxb .) 에탄올 추출물과 실시예 3의 나제이아 플루리(Nageia fleuryi ( Hickel ) de Laub) 에탄올 추출물은 비타민C 표준물질과 비교하여 각각 23.0% 및 49.6% 낮은 항산화능을 나타냈다. As can be seen in FIG. 1 , compared with the vitamin C standard, Pterocarya stenoptera of Example 1 ( Pterocarya ) stenoptera C. DC .) ethanol extract showed 32.0% better antioxidant activity. Garcinia Kowa of Example 2 cowa Roxb . ) Ethanol extract and Nageia fluri of Example 3 ( Nageia fleuryi ( Hickel ) de Laub ) ethanol extract showed lower antioxidant activity by 23.0% and 49.6%, respectively, compared to the vitamin C standard.
실험예Experimental example 2: 항염증 면역활성 효능 테스트 2: Anti-inflammatory immune activity test
(1) 실험방법(1) Experimental method
RAW 264.7 대식세포를 3.0 x 105 세포수/웰 농도로 96웰 플레이트에 같은 양을 나누어서 분주한 후, 세포 착상을 위해 24시간 배양했다. 그 다음에 상기 실시예 1 내지 3에서 제조된 각각의 식물 추출물을 에탄올 용매에 녹여 각각 3, 5, 8, 10, 15, 20, 23, 및 25%(w/v) 농도의 시료를 제조하고, 각각의 시료 100 μl로 세포를 처리하였다. 또한, LPS(농도 10 μg/ml) 100 μl를 세포에 처리하였다. 이후, 24시간 배양한 후, 96웰 플레이트의 상층액 100 μl와 Griess시약 100 μl를 혼합해서 섭씨 37도에서 10분 동안 배양한 후, 540 nm에서 ELISA 기기로 흡광도를 측정하였다.RAW 264.7 macrophages were aliquoted in equal amounts in a 96-well plate at a concentration of 3.0 x 10 5 cells/well, and cultured for 24 hours for cell implantation. Then, each of the plant extracts prepared in Examples 1 to 3 was dissolved in an ethanol solvent to prepare samples with concentrations of 3, 5, 8, 10, 15, 20, 23, and 25% (w/v), respectively, and , cells were treated with 100 μl of each sample. In addition, 100 μl of LPS (
상기와 같은 산화질소 (Nitric Oxide) 분석법은 항염증 면역활성 활성도 측정에 많이 사용되는 분석 방법이다. The nitric oxide (Nitric Oxide) assay as described above is a widely used assay method for measuring anti-inflammatory immune activity.
(2) 실험결과(2) Experiment result
상기 Nitric Oxide Assay 결과를 도 4 내지 도 6에 나타내었다. 도 4는 상기 실시예 1 내지 3에서 제조된 각각의 각각 10%(w/v) 농도의 시료 100 μl를 사용한 결과를 나타냈으며, 도 5에는 실시예 1의 프테로카리아 스테놉테라(Pterocarya stenoptera C. DC.) 에탄올 추출물 3 내지 25%(w/v) 농도의 시료 100 μl를 사용한 결과를 나타냈으며, 도 6에는 실시예 3의 나제이아 플루리(Nageia fleuryi ( Hickel ) de Laub) 에탄올 추출물 3 내지 25%(w/v) 농도의 시료 100 μl를 사용한 결과를 나타내었다. The results of the Nitric Oxide Assay are shown in FIGS. 4 to 6 . 4 shows the results of using 100 μl of each 10% (w/v) concentration sample prepared in Examples 1 to 3, and FIG. 5 shows the Pterocarya stenoptera of Example 1. stenoptera C. DC .)
도 4에서 확인되는 바와 같이, 상기 실시예 1 내지 3에서 제조된 각각의 식물 추출물 시료는 각각 LPS 표준물질에 비해서 19.5%, 16.1% 및 48.7% 더 증가된 항염증 면역활성면역기능을 나타냈다. 이 항염증 면역활성 Assay 실험 조건하에서 3가지 추출물중에서 실시예 3의 나제이아 플루리(Nageia fleuryi ( Hickel ) de Laub) 에탄올 추출물이 제일 항염증 면역활성 활성이 높았다(도 4 내지 6). 이 추출물 성분을 더 조사해보면, 새로운 형태의 항염증 면역활성 compound를 찾아낼 가능성이 있을 것으로 추측된다.As can be seen in FIG. 4 , each of the plant extract samples prepared in Examples 1 to 3 exhibited 19.5%, 16.1%, and 48.7% more increased anti-inflammatory immunoactive immunity compared to the LPS standard, respectively. Among the three extracts under the test conditions of the anti-inflammatory immunoactivity assay, the Nageia fleuryi ( Hickel ) de Laub ethanol extract of Example 3 had the highest anti-inflammatory immunological activity ( FIGS. 4 to 6 ). Further investigation of this extract component is expected to have the potential to discover a new type of anti-inflammatory and immunoactive compound.
실험예Experimental example 3: 세포 안전성 테스트 3: Cell safety testing
(1) 실험방법(1) Experimental method
RAW 264.7 대식세포를 5Х104 세포수/웰 농도로 24 well plate에 같은 양을 나누어 분주했다. 배양접시 바닥에 부착을 위해 24시간 배양한 후, 세포를 LPS(농도 10 μg/ml) 100 μl와 상기 실시예 1 내지 3에서 제조된 각각의 식물 추출물을 에탄올 용매에 녹여 각각 3, 5, 8, 10, 15, 20, 23, 및 25%(w/v) 농도의 시료를 제조하고, 각각의 시료 100 μl로 24시간 처리했다. 표준용액으로 PBS를 넣은 후 같은 조건에서 세포배양을 했다. MTT는 최종 농도 5 mg/mL로 PBS이용하여 용액을 만들었다. 각 웰에 MTT 용액 200 μl를 넣은 후, 섭씨 37도에서 이산화탄소 배양기에서 3시간 30분 동안 배양했다. 상층액을 제거한 후 DMSO 1 ml를 각 웰에 넣었다. 배양접시를 shaking 배양기에 넣어 15분 동안 배양했다. 595 nm에서 ELISA기기 이용해 흡광도를 측정했다.RAW 264.7 macrophages were aliquoted in equal amounts in a 24-well plate at a concentration of 5Х10 4 cells/well. After culturing for 24 hours for attachment to the bottom of the culture dish, 100 μl of LPS (
(2) 실험결과(2) Experiment result
상기 MTT assay로 검사한 결과를 도 7 내지 도 9에 나타내었다. 도 7은 상기 실시예 1 내지 3에서 제조된 각각의 식물 추출물 10%(w/v) 농도의 시료 100 μl를 사용한 결과를 나타냈으며, 도 8에는 실시예 1의 프테로카리아 스테놉테라(Pterocarya stenoptera C. DC.) 에탄올 추출물 3 내지 25%(w/v) 농도의 시료 100 μl를 사용한 결과를 나타냈으며, 도 9에는 실시예 3의 나제이아 플루리(Nageia fleuryi ( Hickel ) de Laub) 에탄올 추출물 3 내지 25%(w/v) 농도의 시료 100 μl를 사용한 결과를 나타내었다. The results of the MTT assay are shown in FIGS. 7 to 9 . 7 shows the results of using 100 μl of a sample having a concentration of 10% (w/v) of each plant extract prepared in Examples 1 to 3, and in FIG. 8, Pterocaria stenoptera of Example 1 ( Pterocarya stenoptera C. DC .)
도 7에서 확인되는 바와 같이, 상기 실시예 1 내지 3에서 제조된 각각의 식물 추출물 시료는 각각 LPS 표준물질에 비해서 각각 2.6%, 4.6% 및 29.30% 낮은 세포성장 활성을 나타내었다. 이러한 결과로부터 나제이아 플루리(Nageia fleuryi (Hickel) de Laub) 에탄올 추출물이 상대적으로 세포독성이 좀 더 강하다고 추측할 수 있다. 7, each of the plant extract samples prepared in Examples 1 to 3 showed cell growth activity lower by 2.6%, 4.6%, and 29.30%, respectively, compared to the LPS standard, respectively. From these results, Nageia fluri ( Nageia fleuryi (Hickel) de Laub ) It can be inferred that the ethanol extract is relatively more cytotoxic.
이상에서 설명한 본 발명은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에 있어 본 발명의 기술적 사상을 벗어나지 않는 범위 내에서 여러 가지 치환, 변형 및 변경이 가능하므로 전술한 실시예 및 첨부된 도면에 의해 한정되는 것이 아니라, 다양한 변형이 이루어질 수 있도록 각 실시예들의 전부 또는 일부가 선택적으로 조합되어 구성될 수 있다.The present invention described above is capable of various substitutions, modifications, and changes within the scope of the present invention for those of ordinary skill in the art to which the present invention pertains, so the above-described embodiments and the accompanying drawings It is not limited by, and all or part of each embodiment may be selectively combined so that various modifications can be made.
Claims (12)
Pterocaria stenoptera stenoptera C. DC .) A cosmetic composition comprising an ethanol extract having anti-inflammatory immune activity and antioxidant activity.
가르시니아 코와(Garcinia cowa Roxb .) 에탄올 추출물 및 나제이아 플루리(Nageia fleuryi ( Hickel ) de Laub) 에탄올 추출물 중에서 선택되는 1종 이상의 성분을 더 포함하는 항염증 면역활성 및 항산화 활성을 갖는 화장료 조성물.
The method of claim 1,
Garcinia Kowa cowa Roxb . ) ethanol extract and Nageia fleuryi ( Nageia fleuryi ( Hickel ) de Laub ) Cosmetic composition having anti-inflammatory immune activity and antioxidant activity further comprising one or more components selected from ethanol extract.
상기 프테로카리아 스테놉테라(Pterocarya stenoptera C. DC.) 에탄올 추출물과, 상기 가르시니아 코와(Garcinia cowa Roxb .) 에탄올 추출물 및 나제이아 플루리(Nageia fleuryi ( Hickel ) de Laub) 에탄올 추출물 중에서 선택되는 1종 이상은 1~3 : 1~3의 중량비로 포함되는 것을 특징으로 하는 항염증 면역활성 및 항산화 활성을 갖는 화장료 조성물.
3. The method of claim 2,
The Pterocaria stenoptera (Pterocarya) stenoptera C. DC .) ethanol extract and the Garcinia cowa ( Garcinia cowa Roxb . ) Ethanol extract and Nageia fleuryi ( Hickel ) de Laub ) At least one selected from ethanol extract is 1-3: Anti-inflammatory and immune activity and antioxidant activity, characterized in that it is included in a weight ratio of 1-3 A cosmetic composition having
상기 화장료 조성물은 용액, 겔, 고체 또는 반죽 무수 생성물, 에멀젼, 현탁액, 마이크로캡슐, 미세과립구 또는 이온형(리포좀), 비이온형의 소낭 분산제의 형태, 크림, 스킨, 로션, 파우더, 연고, 스프레이, 콘실 스틱, 포말(foam) 또는 압축된 추진제를 더 함유한 에어로졸 제형인 것을 특징으로 하는 항염증 면역활성 및 항산화 활성을 갖는 화장료 조성물.
The method of claim 1,
The cosmetic composition is in the form of a solution, gel, solid or kneaded anhydrous product, emulsion, suspension, microcapsule, microgranule or ionic (liposome), non-ionic vesicular dispersion, cream, skin, lotion, powder, ointment, spray , A cosmetic composition having anti-inflammatory immune activity and antioxidant activity, characterized in that it is an aerosol formulation further containing a cone stick, foam or compressed propellant.
Pterocaria stenoptera stenoptera C. DC .) A pharmaceutical composition for preventing and treating inflammatory diseases or diseases caused by free radicals, including an ethanol extract.
가르시니아 코와(Garcinia cowa Roxb .) 에탄올 추출물 및 나제이아 플루리(Nageia fleuryi ( Hickel ) de Laub) 에탄올 추출물 중에서 선택되는 1종 이상의 성분을 더 포함하는 염증성 질환 또는 활성산소로 인해 발생하는 질환의 예방 및 치료용 약학적 조성물.
6. The method of claim 5,
Garcinia Kowa cowa Roxb . ) Ethanol extract and Nageia fleuryi ( Nageia fleuryi ( Hickel ) de Laub ) Inflammatory diseases or diseases caused by free radicals further comprising one or more components selected from ethanol extracts for the prevention and treatment of a pharmaceutical composition for treatment.
상기 프테로카리아 스테놉테라(Pterocarya stenoptera C. DC.) 에탄올 추출물과, 상기 가르시니아 코와(Garcinia cowa Roxb .) 에탄올 추출물 및 나제이아 플루리(Nageia fleuryi ( Hickel ) de Laub) 에탄올 추출물 중에서 선택되는 1종 이상은 1~3 : 1~3의 중량비로 포함되는 것을 특징으로 하는 염증성 질환 또는 활성산소로 인해 발생하는 질환의 예방 및 치료용 약학적 조성물.
7. The method of claim 6,
The Pterocaria stenoptera (Pterocarya) stenoptera C. DC .) ethanol extract and the Garcinia cowa ( Garcinia cowa Roxb . ) ethanol extract and Nageia fleuryi ( Hickel ) de Laub ) At least one selected from ethanol extract is 1-3: Due to inflammatory disease or active oxygen, characterized in that it is included in a weight ratio of 1-3 A pharmaceutical composition for preventing and treating diseases that occur.
상기 염증성 질환은 알러지성 천식, 알러지성 비염, 알러지성 점막염, 두드러기 및 아나필락스(anaphylax)를 포함하는 알러지성 질환, 경피증(systemic sclerosis), 피부근염(dermatomyositis) 및 포함체 근육염(inclusion body myositis)을 포함하는 근병증, 관절염, 아토피성 피부염, 건선, 천식, 다발성 경화증, ssRNA 및 dsRNA 바이러스 감염증, 패혈증, 다발성 연골염, 경피증, 습진, 통풍, 치주질환, 베체트 증후군, 부종, 맥관염, 가와사키병, 당뇨병성 망막염, 자가 면역 췌장염, 혈관염, 사구체 신염, 급성 및 만성 기관지염, 또는 인플루엔자 감염증이며,
상기 활성산소로 인해 발생하는 질환은 동맥경화증, 루게릭병, 파킨슨병, 알츠하이머, 근위축색경화증 및 헌팅톤병을 포함하는 퇴행성 신경질환, 심근경색, 협심증, 관상동맥질환, 허혈성 심장질환을 포함하는 심혈관 질환, 뇌졸중을 포함하는 허혈성 뇌질환, 또는 활성산소에 의해 발생되는 노화인 것을 특징으로 하는 염증성 질환 또는 활성산소로 인해 발생하는 질환의 예방 및 치료용 약학적 조성물.
6. The method of claim 5,
The inflammatory diseases include allergic asthma, allergic rhinitis, allergic mucositis, urticaria and allergic diseases including anaphylax, systemic sclerosis, dermatomyositis and inclusion body myositis. ) including myopathy, arthritis, atopic dermatitis, psoriasis, asthma, multiple sclerosis, ssRNA and dsRNA virus infection, sepsis, polychondritis, scleroderma, eczema, gout, periodontal disease, Behcet's syndrome, edema, vasculitis, Kawasaki disease, diabetic retinitis, autoimmune pancreatitis, vasculitis, glomerulonephritis, acute and chronic bronchitis, or influenza infection;
Diseases caused by the free radicals include arteriosclerosis, Lou Gehrig's disease, Parkinson's disease, Alzheimer's, amyotrophic sclerosis and degenerative neurological disease including Huntington's disease, myocardial infarction, angina, coronary artery disease, cardiovascular disease including ischemic heart disease , ischemic brain disease including stroke, or inflammatory disease characterized in that aging caused by free radicals or a pharmaceutical composition for the prevention and treatment of diseases caused by free radicals.
Pterocaria stenoptera stenoptera C. DC .) A food composition comprising an ethanol extract having anti-inflammatory immune activity and antioxidant activity.
가르시니아 코와(Garcinia cowa Roxb .) 에탄올 추출물 및 나제이아 플루리(Nageia fleuryi ( Hickel ) de Laub) 에탄올 추출물 중에서 선택되는 1종 이상의 성분을 더 포함하는 항염증 면역활성 및 항산화 활성을 갖는 식품 조성물.
10. The method of claim 9,
Garcinia Kowa cowa Roxb . ) ethanol extract and Nageia fleuryi ( Nageia fleuryi ( Hickel ) de Laub ) Food composition having anti-inflammatory immune activity and antioxidant activity further comprising one or more components selected from ethanol extract.
상기 프테로카리아 스테놉테라(Pterocarya stenoptera C. DC.) 에탄올 추출물과, 상기 가르시니아 코와(Garcinia cowa Roxb .) 에탄올 추출물 및 나제이아 플루리(Nageia fleuryi ( Hickel ) de Laub) 에탄올 추출물 중에서 선택되는 1종 이상은 1~3 : 1~3의 중량비로 포함되는 것을 특징으로 하는 항염증 면역활성 및 항산화 활성을 갖는 식품 조성물.
11. The method of claim 10,
The Pterocaria stenoptera (Pterocarya) stenoptera C. DC .) ethanol extract and the Garcinia cowa ( Garcinia cowa Roxb . ) Ethanol extract and Nageia fleuryi ( Hickel ) de Laub ) At least one selected from ethanol extract is 1-3: Anti-inflammatory and immune activity and antioxidant activity, characterized in that it is included in a weight ratio of 1-3 A food composition having
상기 식품 조성물은 건강기능성 식품 조성물인 것을 특징으로 하는 항염증 면역활성 및 항산화 활성을 갖는 식품 조성물.
10. The method of claim 9,
The food composition is a food composition having anti-inflammatory immune activity and antioxidant activity, characterized in that it is a health functional food composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200131756A KR102428082B1 (en) | 2020-10-13 | 2020-10-13 | Cosmetic composition, pharmaceutical composition, and food composition comprising pterocaria stenoptera extract, which have anti-inflammatory immune activity and antioxidant activity and provide excellent effect on muscle cell generation for strengthening muscle strength or muscle in the elderly |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200131756A KR102428082B1 (en) | 2020-10-13 | 2020-10-13 | Cosmetic composition, pharmaceutical composition, and food composition comprising pterocaria stenoptera extract, which have anti-inflammatory immune activity and antioxidant activity and provide excellent effect on muscle cell generation for strengthening muscle strength or muscle in the elderly |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220048640A true KR20220048640A (en) | 2022-04-20 |
| KR102428082B1 KR102428082B1 (en) | 2022-08-01 |
Family
ID=81395380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200131756A KR102428082B1 (en) | 2020-10-13 | 2020-10-13 | Cosmetic composition, pharmaceutical composition, and food composition comprising pterocaria stenoptera extract, which have anti-inflammatory immune activity and antioxidant activity and provide excellent effect on muscle cell generation for strengthening muscle strength or muscle in the elderly |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102428082B1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040060729A (en) | 2002-12-27 | 2004-07-06 | 주식회사한국신약 | Extract of Cercis chinensis having anti-oxidant activity and anti-aging activity, and cosmetical composition containing the extract for anti-oxidation, skin-aging protection and wrinkle improvement |
| JP2007004390A (en) * | 2005-06-22 | 2007-01-11 | Ntt Docomo Inc | Sensor network system, cluster formation method, and sensor node |
| CN104274831A (en) * | 2013-07-10 | 2015-01-14 | 苏德培 | Composition based on naturally derived peptide and inflammation inhibitor and/or anti-oxidation compound |
-
2020
- 2020-10-13 KR KR1020200131756A patent/KR102428082B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040060729A (en) | 2002-12-27 | 2004-07-06 | 주식회사한국신약 | Extract of Cercis chinensis having anti-oxidant activity and anti-aging activity, and cosmetical composition containing the extract for anti-oxidation, skin-aging protection and wrinkle improvement |
| JP2007004390A (en) * | 2005-06-22 | 2007-01-11 | Ntt Docomo Inc | Sensor network system, cluster formation method, and sensor node |
| CN104274831A (en) * | 2013-07-10 | 2015-01-14 | 苏德培 | Composition based on naturally derived peptide and inflammation inhibitor and/or anti-oxidation compound |
Non-Patent Citations (2)
| Title |
|---|
| Exploration of radical scavenging ability and gastric cancer prevention effect of folk plants * |
| Jeong Ji-eun et al. Exploring the radical scavenging ability and gastric cancer prevention effect of folk plants. Cancer prevention research, 2011 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102428082B1 (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005072684A1 (en) | Process for producing maca extract | |
| KR20190050667A (en) | Composition for anti-oxidation or anti-inflammation comprising barley sprouts extract as an active ingredient | |
| KR20210014231A (en) | Composition for prevention or treatment of muscular disorders or improvement of muscular functions comprising seaweeds extract | |
| KR101320738B1 (en) | The method of extracting carotinoid pigments of micro algae and composition comprising the extracted fucoxanthin for preventing or treating obesity or diabetes | |
| KR101793208B1 (en) | A compostion comprising Cotoneaster horizontalis Decne extract having anti-oxidation or anti-inflammation activity | |
| KR101611853B1 (en) | Aster glehni fractions or compounds isolated therefrom having anti-inflammatory activity | |
| KR100883992B1 (en) | Composition containing extracts of Zanthoxylum piperitum DC or compounds isolated therefrom for the prevention and treatment of cardiovascular diseases | |
| KR20190057225A (en) | A composition having anti-oxidation or anti-inflammation comprising Selaginella tamariscina extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
| KR102052523B1 (en) | A composition having anti-bacterial activity comprising Selaginella tamariscina extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
| JP4537024B2 (en) | Inflammatory disease preventive / therapeutic agent | |
| KR102428082B1 (en) | Cosmetic composition, pharmaceutical composition, and food composition comprising pterocaria stenoptera extract, which have anti-inflammatory immune activity and antioxidant activity and provide excellent effect on muscle cell generation for strengthening muscle strength or muscle in the elderly | |
| KR102154092B1 (en) | A compostion comprising Torreya nucifera seed extract or its fraction having anti-oxidation or anti-inflammation activity | |
| KR102058022B1 (en) | Composition for antioxidant and anti-inflammatory comprising fraction of Ledum palustre L. extract as effective component | |
| KR20180098737A (en) | A composition having anti-oxidation or anti-inflammation comprising Selaginella tamariscina extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
| KR101768280B1 (en) | A composition comprising Carpinus pubescens extracts having anti-oxidation or anti-inflammation activity | |
| KR101891408B1 (en) | A composition comprising ganoderma lucidum grown on hulled barley extracts having anti-oxidation or anti-inflammation activity | |
| KR101430350B1 (en) | A composition comprising Decaisnea insignis extracts having anti-oxidation or anti-inflammation activity | |
| KR20170045770A (en) | A compostion comprising Osmanthus matsumuranus extract having anti-oxidation or anti-inflammation activity | |
| KR102129461B1 (en) | A composition having anti-bacterial activity comprising Selaginella tamariscina extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
| KR102600557B1 (en) | A composition having anti-inflammation activity comprising compounds isolated from the fraction of the Podocarpus macrophyllus extracts as an active ingredient | |
| KR102104425B1 (en) | Composition for anti-oxidant and anti-inflammatory comprising eritadenine as effective component | |
| KR102671693B1 (en) | Composition for antioxidant and anti-inflammatory comprising extract of chondracanthus tenellus hommersand as an active ingredient | |
| KR101430352B1 (en) | A composition comprising Ophiorrhiza cantonensis extracts having anti-oxidation or anti-inflammation activity | |
| KR102373119B1 (en) | A composition having anti-inflammation activity comprising compounds isolated from the fraction of the Crepidiastrum sonchifolium extracts as an active ingredient | |
| KR101430354B1 (en) | A composition comprising Psychotria rubra extracts having anti-oxidation or anti-inflammation activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |